Not only Pfizer won’t work away, they don’t even want to waste time on Covid tool deployment, in other words the Covid screen FDA is not if but when.
1 The scheme was made to shield Pfizer from competitors/3rd party business step in 2 BOD was required to prioritize Covid screen R&D. With Pfizer’s help 1500 ppl data collected at its fastest to do a readout and train algorithms. Probably US trial recruitment has started, thanks to 3m dollars cash injection, and 1m bonus on milestone 3 In case the scheme is voted out, Pfizer still has the remaining R&D in play. They can give up on acquiring 100% of RAP (they underestimated the value of the rest of business), but as long as The Covid license deal can maximize their benefit, they will finally agree with the deal.
I am expecting Sleep check and DX commercialization further down their way after the vote, then we will sit on top of 20.8c (current preferred)+ Covid FDA value.
Hold on another month and vote No!
RAP Price at posting:
13.5¢ Sentiment: Buy Disclosure: Held